白细胞介素-1β和核因子κB激酶亚基β的抑制剂高表达对中国肝癌分期Ⅰ~Ⅱ期肝细胞癌患者术后预后的影响  

The influence of high expression of interleukin-1βand nuclear factor kappa B kinase subunitβinhibitors on the postoperative prognosis of Chinese liver cancer patients with stageⅠ-Ⅱhepatocellular carcinoma

作　　者：李浩然 牟晓静 罗定安 张懋 王静[1] 胡维昱[1] 吴力群[1] 韩冰[1] Li Haoran;Mou Xiaojing;Luo Dingan;Zhang Mao;Wang Jing;Hu Weiyu;Wu Liqun;Han Bing(Department of Hepatobiliary and Pancreatic Surgery,Affiliated Hospital of Qingdao University,Qingdao 266071,China;Department of the First Stationed Outpatient,the 971 Naval Hospital,Qingdao 266071,China)

机构地区：[1]青岛大学附属医院肝胆胰外科,266071 [2]海军第九七一医院第一派驻门诊部,青岛266071

出　　处：《中华实验外科杂志》2021年第10期1890-1893,共4页Chinese Journal of Experimental Surgery

基　　金：青岛市科技惠民计划项目(18-6-1-89-nsh);山东省重点研发计划(2018GSF118233);青岛市市南区科技计划(2018-4-018-YY)。

摘　　要：目的探讨肿瘤组织中白细胞介素-1β(IL-1β)和核因子κB激酶亚基β的抑制剂(IKKβ)的表达与肝细胞癌(HCC)患者术后预后的关系。方法采用免疫组织化学方法检测87例于2000年1月至2012年12月在青岛大学附属医院接受手术切除的HCC患者肿瘤组织中IL-1β和IKKβ的表达。使用统计学相关性分析及卡方检验的方法分析IL-1β和IKKβ表达与临床病理因素的相关性以及与预后的关系。结果 IL-1β和IKKβ表达量在HCC中呈正相关(r=0.229,P<0.05)。IKKβ的高表达以及IL-1β和IKKβ共同高表达的患者总体生存期更长[(86.507±7.749)个月比(54.471±6.275)个月、(92.272±8.409)个月比(58.723±6.710)个月],差异有统计学意义(χ^(2)=4.456、6.160,P<0.05);IL-1β、IKKβ的高表达以及IL-1β和IKKβ共同高表达的患者无瘤生存期更长[(36.886±3.862)个月比(14.792±4.491)个月、(39.790±4.707)个月比(21.473±3.617)个月、(44.942±5.155)个月比(20.957±3.284)个月],差异有统计学意义(χ^(2)=11.416、7.987、11.594,P<0.05)。此外,多变量Cox回归模型显示IL-1β和IKKβ的表达水平是总体生存期的独立风险因素[风险比(HR)=0.462,95%可信区间(CI):0.225~0.946,P<0.05],天冬氨酸氨基转移酶水平以及IL-1β和IKKβ共同表达水平是无瘤生存期的独立风险因素(HR=1.821,95%CI:1.060~3.129,P<0.05;HR=0.529,95%CI:0.282~0.991,P<0.05)。结论 IL-1β和IKKβ高表达有利于肝细胞癌患者预后。Objective To investigate the relationship between the expression of interleukin-1β(IL-1β)and nuclear factor kappa B kinase subunitβ(IKKβ)in tumor tissues and the prognosis of patients with hepatocellular carcinoma(HCC).Methods The immunohistochemical method was used to detect the expression of IL-1βand IKKβin the tumor tissues of HCC patients.Statistical correlation analysis and chi-square test were used to analyze the correlation between the expression of IL-1βand IKKβand clinicopathological factors and the relationship with prognosis.Results The expression levels of IL-1βand IKKβwere positively correlated in HCC(r=0.229,P<0.05).Patients with high expression of IKKβand high expression of IL-1βand IKKβhave longer overall survival[(86.507±7.749)vs.(54.471±6.275)month,(92.272±8.409)vs.(58.723±6.710)month],and the difference is statistically significant(χ^(2)=4.456,6.160,P<0.05);patients with high expression of IL-1βand IKKβand high expression of IL-1βand IKKβhave longer tumor-free survival[(36.886±3.862)vs.(14.792±4.491)month,(39.790±4.707)vs.(21.473±3.617)month,(44.942±5.155)vs.(20.957±3.284)month],the difference was statistically significant(χ^(2)=11.416,7.987,11.594,P<0.05).In addition,the multivariate Cox regression model showed that the expression levels of IL-1βand IKKβwere independent risk factors for overall survival[hazard ratio(HR)=0.462,95%confidence interval(CI):0.225-0.946,P<0.05],aspartate aminotransferase levels,and the co-expression level of IL-1βand IKKβis an independent risk factor for tumor-free survival(HR=1.821,95%CI:1.060-3.129,P<0.05;HR=0.529,95%CI:0.282-0.991,P<0.05).Conclusion The high expression of IL-1βand IKKβis beneficial to the prognosis of patients with hepatocellular carcinoma.

关 键 词：白细胞介素-1Β 核因子κB激酶亚基β的抑制剂 肝细胞癌 复发 生存 

分 类 号：R735.7[医药卫生—肿瘤]